Fast Five Quiz: HER2+ Metastatic Breast Cancer Management

Winston Tan, MD


January 10, 2022

According to recommendations from the American Society of Clinical Oncology (ASCO) for the management of HER2+ metastatic breast cancer, HER2-targeted antibody therapy is recommended along with chemotherapy, except for those patients with cardiac comorbidities, specifically congestive heart failure or significantly compromised left ventricular fraction (systolic heart failure). These patients should be evaluated on a case-by-case basis.

Optimal duration of chemotherapy is 4-6 months, until maximum response is reached (ie, absence of disease progression and toxicity levels). HER2-targeted therapies can be continued concomitantly until disease progression or unacceptable toxicity.

For patients with HER2+ and estrogen receptor–positive/progesterone receptor–positive metastatic breast cancer, standard first-line therapy or, for selected patients, endocrine therapy plus HER2-targeted therapy or endocrine therapy alone, is recommended.

Learn more about the treatment of HER2+ metastatic breast cancer.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.